Switching from Neutral Protamine Hagedorn (NPH) Insulin to Insulin Glargine 300 U/mL in Older and Younger Patients with Type 2 Diabetes: A Post Hoc Analysis of a Multicenter, Prospective, Observational Study.
Elderly
Glargine 300
Hypoglycemia
Insulin
NPH
Type 2 diabetes
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
20
10
2021
accepted:
23
12
2021
pubmed:
17
1
2022
medline:
17
1
2022
entrez:
16
1
2022
Statut:
ppublish
Résumé
Older age and longer disease duration are key risk factors for hypoglycemia in patients with type 2 diabetes (T2D) who receive insulin. Previous studies have shown that insulin glargine 300 U/mL (Gla-300) improves glycemic control and reduces the risk of hypoglycemia, but whether this effect is observed in older patients switching from neutral protamine Hagedorn (NPH) insulin is unclear. In this multicenter, observational study involving patients with T2D aged ≥ 18 years with glycated hemoglobin (HbA A total of 469 participants were included in the study. From baseline to 6 months after switching to Gla-300, mean HbA The switch from NPH insulin to Gla-300 improved glycemic control in older patients with T2D and in those with a longer disease duration. Older patients with T2D and those with a longer disease duration benefited even more from the switch to Gla-300 than younger patients and those with a shorter disease duration, with significantly greater reductions in the risk of hypoglycemia.
Identifiants
pubmed: 35034328
doi: 10.1007/s13300-021-01199-4
pii: 10.1007/s13300-021-01199-4
pmc: PMC8873339
doi:
Types de publication
Journal Article
Langues
eng
Pagination
301-310Informations de copyright
© 2022. The Author(s).
Références
BMJ. 2011 Nov 24;343:d6898
pubmed: 22115901
JAMA Intern Med. 2016 Jul 1;176(7):1023-5
pubmed: 27273335
Diabetes Obes Metab. 2013 Dec;15(12):1085-92
pubmed: 23683002
J Med Econ. 2011;14(5):646-55
pubmed: 21854191
Diabet Med. 2003 Dec;20(12):1016-21
pubmed: 14632703
Diabetes Care. 2019 Jan;42(Suppl 1):S139-S147
pubmed: 30559238
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976
J Diabetes Res. 2020 Apr 8;2020:8751348
pubmed: 32337298
Diabetes Ther. 2019 Apr;10(2):617-633
pubmed: 30767173
Diabetes Obes Metab. 2021 Jul;23(7):1588-1593
pubmed: 33687748
Diabetes Obes Metab. 2019 Nov;21(11):2384-2393
pubmed: 31264346
Diabetologia. 2007 Jun;50(6):1140-7
pubmed: 17415551
Biomed Res Int. 2014;2014:906103
pubmed: 24689062
BMJ Open Diabetes Res Care. 2020 Feb;8(1):
pubmed: 32107264
Drugs Aging. 2004;21(8):511-30
pubmed: 15182216
Diabetes Ther. 2021 Jul;12(7):2049-2058
pubmed: 34160790
Diabetes Ther. 2021 Apr;12(4):1073-1097
pubmed: 33650085
Diabetes Care. 2005 Dec;28(12):2948-61
pubmed: 16306561
Diabet Med. 2006 Jul;23(7):750-6
pubmed: 16842479
Diabet Med. 1998 May;15(5):398-401
pubmed: 9609362
Diabetes Metab. 2010 Oct;36 Suppl 3:S64-74
pubmed: 21211739
Postgrad Med. 2010 May;122(3):129-37
pubmed: 20463422
Arch Intern Med. 2011 Feb 28;171(4):362-4
pubmed: 21357814
Diabetes Ther. 2021 Mar;12(3):913-930
pubmed: 33604804
Diabetes Care. 2011 Jun;34(6):1329-36
pubmed: 21505211
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 31825487
Diabetes Metab. 2020 Apr;46(2):110-118
pubmed: 30366067